CT-P39 — Competitive Intelligence Brief

CT-P39 (CT-P39) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-L1 inhibitor; monoclonal antibody. Area: Oncology.

phase 3 PD-L1 inhibitor; monoclonal antibody PD-L1 (Programmed Death Ligand 1) Oncology Biologic

Target snapshot

CT-P39 (CT-P39) — Celltrion. CT-P39 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CT-P39 TARGET	CT-P39	Celltrion	phase 3	PD-L1 inhibitor; monoclonal antibody	PD-L1 (Programmed Death Ligand 1)
Adebrelimab combined with SOX regimen	Adebrelimab combined with SOX regimen	Yang Jianjun, PhD	marketed	PD-L1 inhibitor	PD-L1
Atezolizumab Injection [Tecentriq]	Atezolizumab Injection [Tecentriq]	Nykode Therapeutics ASA	marketed	PD-L1 inhibitor	PD-L1
PD-1 / PD-L1 monoclonal antibody	PD-1 / PD-L1 monoclonal antibody	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	marketed	PD-1/PD-L1 inhibitor	PD-1 and/or PD-L1
AB	AB	GlaxoSmithKline	marketed	PD-L1 inhibitor	PD-L1
Avelumab first-line maintenance	Avelumab first-line maintenance	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	PD-L1 inhibitor	PD-L1
Atezolizumab(Tecentriq)	Atezolizumab(Tecentriq)	Samsung Medical Center	phase 3	PD-L1 inhibitor	PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-L1 inhibitor; monoclonal antibody class)

1. Celltrion · 1 drug in this class